Sanofi's 2022Q1 Performance: China Increased by 13.4%! Dupixent Up 45.7%

On April 28, Sanofi announced its 2022Q1 results, achieving revenue of 9.674 billion euros, a year-on-year increase of 8.6%. Among them, the pharmaceutical business income totaled 7.326 billion euros (+11.6%), the vaccine business income was 1.02 billion euros (+6.8%), and the consumer healthcare business income was 1.328 billion euros (+17%).

In terms of geographical distribution of revenue, Russia provided Sanofi with the strongest growth driver (+34.4%), followed by the Chinese market, with a year-on-year increase of 13.4% (901 million euros), mainly benefiting from Dupixent (Dupliu). monoclonal antibodies) and the push for vaccines. However, the purchase of insulin with volume is expected to be implemented in May 2022, and Sanofi expects that the sales of the two winning products, Toujeo/Lantus China, will drop by about 30% in 2022.

From the perspective of specific varieties, Dupixent is the dominant product and will still be the product that Sanofi relies on most in the short term. Revenue for the quarter rose 45.7 percent year-on-year to €1,614 million. At present, the product is far ahead in the number of branded new drug prescriptions (NBRx) in type 2 inflammatory diseases such as dermatology, allergy, and respiratory departments.

Although Sanofi announced on February 19 this year that Dupixent had failed a Phase III study in chronic spontaneous urticaria, the product still made several important advances this quarter, including: 1) Submitted in the United States and Europe for the treatment of nodular urticaria Marketing application for prurigo (PN); 2) FDA and EU accepted the sBLA for the treatment of eosinophilic esophagitis (EOE) and granted priority review; 3) The new indication for the treatment of 6-11 years old asthma was approved in Europe; 4 ) has submitted a marketing application in the United States for the treatment of atopic dermatitis in children 6 months to 5 years of age.

Sales of Kevzara (sarilumab), an IL-6 receptor inhibitor developed in partnership with Regeneron, increased by 61.4% to EUR 95 million, due to increased global demand for IL-6 receptor blockers and support for Temporary shortage of zizumab.

In the tumor field, the PD-1 monoclonal antibody Libtayo (cemiplimab) and the CD38 monoclonal antibody Sarclisa (isatuximab) are still in the stage of explosive growth, but the base is still small. Jevtana's sales fell 25.4% to 98 million euros in the first quarter due to the impact of generic drugs. However, Jevtana currently has 4 patents (US 7,241,907, US 8,927,592, US 10,583,110 and US 10,716,777) protected by the Orange Book. Sanofi has filed patent infringement lawsuits in the U.S. District Court against generic applicants of the '110 patent, the '777 patent and the '592 patent, and has reached settlements with some of the defendants, while the litigation against the remaining defendants is still ongoing.

In addition to the above-mentioned progress on Dupixent, Sanofi has made many progress in the field of rare diseases, new crown vaccines, and anti-tumor:

On February 4, the FDA approved the first complement C1s antibody sutimlimab (Enjaymo) for the treatment of cold agglutinin disease (CAD) to reduce the need for red blood cell transfusions due to hemolysis in patients with CAD.

On February 24, jointly with GSK, submitted a marketing application for SARS-CoV-2 adjuvanted recombinant protein vaccine to the European Medicines Agency and the FDA;
and Regeneron announced the voluntary withdrawal of Libtayo (cemiplimab) as a second-line sBLA for advanced cervical cancer.
The oral selective estrogen degrader (SERD) amcenestran failed the phase II AMEERA-3 study in patients with locally advanced or metastatic ER+/HER2- breast cancer that had progressed before and after hormonal therapy and did not achieve improvement in progression-free survival (PFS) primary endpoint.
In the face of the patent cliff crisis, Sanofi is also working hard to supplement its product pipeline through cooperation, transactions and mergers. During the quarter, Sanofi entered into a number of cooperation, transaction and M&A matters:

On February 8, the acquisition of Amunix was completed to expand the T cell engager (TCE) and cytokine therapy pipeline
On March 2, a cooperation agreement was reached with Tianyan Pharmaceutical. Tianyan Pharmaceutical used its safe antibody SAFEbody technology to help Sanofi develop a new generation of monoclonal and double-antibody precision masked safety antibodies;
On March 15, reached a strategic cooperation with BlackstoneLife, BlackstoneLife will pay up to 300 million euros to advance the development of Sarclisa subcutaneous formulation;
On March 16, it entered into an exclusive cooperation agreement with Seagen, a leader in the ADC field, to design, develop and commercialize antibody-drug conjugates (ADCs) for up to 3 cancer sites.
In addition, Sanofi also updated and released the company's new logo on February 3, conveying Sanofi's new visual image and new business focus, representing the company's new starting point.

For full-year 2022 results, Sanofi expects low double-digit growth.